Stock AGN ALGERNON PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Market Closed - Canadian Securities Exchange
Other stock markets
 11:01:40 2024-05-03 am EDT 		5-day change 1st Jan Change
0.11 CAD 0.00% Intraday chart for Algernon Pharmaceuticals Inc. -15.38% +69.23%
Apr. 30 Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Apr. 10 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
CI
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024
AQ
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
AQ
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
AQ
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding
CI
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.017 million in funding
CI
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
AQ
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset
CI
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
AQ
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company
MT
Canadian Investment Regulatory Organization Trade Resumption - AGN
AQ
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
AQ
Canadian Investment Regulatory Organization Trading Halt - AGN
AQ
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.
CI
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
AQ
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023
CI
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
CI
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
MT
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Algernon Pharmaceuticals Inc.